Bladder cancer drug avelumab shows promise as Long-Term maintenance therapy

NCT ID NCT05366725

First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 28 times

Summary

This study looked at how well the drug avelumab works as a maintenance treatment for people with advanced bladder cancer that hasn't gotten worse after initial chemotherapy. The study included 106 adults and followed them for about 4 years to track safety and how long they lived. The goal was to see if continuing treatment with avelumab helps keep the cancer under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UROTHELIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beatson West of Scotland Cancer Centre

    Glasgow, G12 0YN, United Kingdom

  • Churchill Hospital

    Oxford, OX3 7LE, United Kingdom

  • Clatterbridge Hospital

    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom

  • Guy's and St Thomas' Hospital

    London, SE1 9RT, United Kingdom

  • Lister Hospital

    Stevenage, SG1 4AB, United Kingdom

  • Royal Preston Hospital

    Preston, PR2 9HT, United Kingdom

  • Royal Surrey County Hospital

    Guildford, GU2 7XX, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • University College London Hospital

    London, NW1 2PG, United Kingdom

  • University Hospitals Bristol

    Bristol, BS1 3NU, United Kingdom

Conditions

Explore the condition pages connected to this study.